PTS Pulse

0
by in

PTS Collect Capillary Tubes Sell Sheet

Speeds Blood Collection and Ensures Savings

PTS CollectTM capillary tubes provide significant savings over traditional transfer tube technology—especially for applications where exact volumes are required. Using a single glass tube with plastic casing, PTS Collect capillary tubes provide consistent self-wicking technology to preset volumes.

Increased Efficiency in Workflow
  • Ease-of-use with no assembly
  • Glass tube ensures easy blood collection
  • Only one item to inventory (no plunger)
    • Increased Efficiency in Workflow
  • One-hand blood collection
  • Bulb-squeeze dispensing technology ensures consistent performance
    • 0
    by in

    CardioChek PA Sell Sheet

     
    PTS Diagnostics
    4600 Anson Blvd, Whitestown, IN 46075 USA
    Office: +1 (317) 870-5610 FAX: +1 (317) 870-5608
    Toll-Free in the US: 1 9877) 870-5610
    CardioChek and PTS Panels are trademarks of Polymer Technology Systems, Inc. © 2017 Polymer Technology Systems, Inc. MKG 001169 Rev. 2 01/17
    0
    by in

    CardioChek Plus Sell Sheet

    0
    by in

    CLSI Procedure: A1CNow+ Test System

    A1CNow®+

    Procedure: A1CNow®+ Test System

    LIT 001634 Rev. 0 04/15
    0
    by in

    A1CNow+ System: Abstract Multi-Center Accuracy Assessment

    Multi-center accuracy assessment of a1cnow+: a disposable system for monitoring hemoglobin a1c

    Author Block: KEITH A. MOSKOWITZ, BEATRIZ WALSH, MARCY SHIPWASH, STEPHANIE MIHANE, KARMEN
    MERCER, EMILY SUSCHA, MARIA SHAFAI, CORINA LINDKE, CHARLES XIE, JAMES A. ANDERSON, Indianapolis,
    IN, Santa Cruz, CA, Thomasville, NC, Denver, CO, Sunnyvale, CA

    Abstract:

    Background: HbA1c is indicated for diagnoses (Dx) of diabetes using central laboratory (CL) analyzers. Point of
    Care (POC) Hb A1c analyzers offer advantages such as real time consultation, but are not indicated for
    screening or Dx due to perceived inaccuracy. CAP criteria allow +/- 6 % bias and WHO allows POC when it is
    the only option or when a quality assurance (QA) program exists. POC instruments are often CLIA waived thus
    not subject to QA proficiency testing. Accordingly, the accuracy of PTS Diagnostics A1CNow+ POC Hb A1c test
    was evaluated relative to CL Hb A1c systems.

    Methods: Blood from 94 subjects was taken from three US wellness centers: Finger stick blood was used to
    test A1CNow+. EDTA venous blood was used for the Roche Cobas Integra and Abbott Architect. Heparin
    venous blood was used for the Tosoh G8 comparator. Correlation regression analyses were performed to
    determine accuracy and % difference to assess bias. Clinical risk stratification was assessed using Hb A1c
    category (cat) cut points of < 5.7; 5.7-6.4; and ≥ 6.5 and if differences resulted in 0, 1, or 2 cat change. Fisher’s
    exact test was used to assess differences associated with risk.

    Results: In total, slopes were 1.020 and 0.986 for CL and A1cNow+ relative to Tosoh (p = 0.63); r of 0.99 and
    0.96, and intercept 0.24 and 0.13, respectively (p = 0.64). Bias was 0.3% for A1cNow+ and 3.8% for CL. Risk
    was unchanged in 81.7% of CL and 77.7% of A1CNow+ measures, resulting in non-statistical (p= 0.54) cat 1
    differences between the POC and CL methods. There were no cat 2 risk differences regardless of method.

    Conclusions: A1CNow+ was at least as accurate in measuring Hb A1c relative to three CL analyzers and well
    within the 6% CAP guideline for bias. Risk stratification revealed no differences between the CL and A1CNow+
    in classifying the patient state. Ease of use and disposability of A1CNow+ should help assess Hb A1c in
    situations where CL analyzers are unavailable and to provide physicians with real time information to better
    manage diabetes.

    Author Disclosure Information:
    K.A. Moskowitz: Employee; Author; PTS Diagnostics.  Stock/Shareholder; Author; PTS Diagnostics. B. Walsh:
    None. M. Shipwash: None. S. Mihane: None. K. Mercer: Employee; Author; PTS Diagnostics.
    Stock/Shareholder; Author; PTS Diagnostics. E. Suscha: Employee; Author; PTS Diagnostics. M. Shafai:
    Employee; Author; PTS Diagnostics. C. Lindke: Employee; Author; PTS Diagnostics. C. Xie: Employee; Author;
    PTS Diagnostics. Stock/Shareholder; Author; PTS Diagnostics. J.A. Anderson: Employee; Author; PTS
    Diagnostics. Stock/Shareholder; Author; PTS Diagnostics.
    Category (Complete): 12-A Clinical Therapeutics/New Technology–Glucose Monitoring and Sensing
    Presentation Preference (Complete): Oral Preferred
    Financial Support (Complete):
    * ADA Support: No

    Keyword (Complete): A1c ; Accuracy
    Payment (Complete): Your credit card order has been processed on Monday 12 December 2016 at 4:44 PM.
    Status: Complete

    LIT 001815 r0 9/17